Literature DB >> 27135305

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms.

Natalia Curto-García1, Claire N Harrison2, Donal P McLornan2, Deepti H Radia2.   

Abstract

Entities:  

Keywords:  JAK1/2 inhibitor; fedratinib; myelofibrosis; thiamine

Mesh：

Substances：

Year:  2016        PMID： 27135305     DOI： 10.1111/bjh.14128

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Fedratinib in myelofibrosis.

Authors:  Ann Mullally; John Hood; Claire Harrison; Ruben Mesa
Journal:  Blood Adv       Date:  2020-04-28

2.  A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.

Authors:  Naseema Gangat; Amy Phelps; Terra L Lasho; Christy M Finke; Rangit Vallapureddy; Curtis A Hanson; Rhett P Ketterling; Mrinal M Patnaik; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2019-01-24       Impact factor: 11.037

Review 3.  The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.

Authors:  Jeanne Palmer; Ruben Mesa
Journal:  Ther Adv Hematol       Date:  2020-05-15

Review 4.  Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.

Authors:  Moshe Talpaz; Jean-Jacques Kiladjian
Journal:  Leukemia       Date:  2020-07-09       Impact factor: 11.528

Review 5.  Management of myelofibrosis after ruxolitinib failure.

Authors:  Claire N Harrison; Nicolaas Schaap; Ruben A Mesa
Journal:  Ann Hematol       Date:  2020-03-20       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.